CN105829312A - 一种n-苄基色胺酮衍生物及其制备方法和应用 - Google Patents

一种n-苄基色胺酮衍生物及其制备方法和应用 Download PDF

Info

Publication number
CN105829312A
CN105829312A CN201480067750.9A CN201480067750A CN105829312A CN 105829312 A CN105829312 A CN 105829312A CN 201480067750 A CN201480067750 A CN 201480067750A CN 105829312 A CN105829312 A CN 105829312A
Authority
CN
China
Prior art keywords
compound
group
formula
ketone
ido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201480067750.9A
Other languages
English (en)
Other versions
CN105829312B (zh
Inventor
杨青
匡春香
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinjiang Hengyuan Technology Development Co ltd
Fudan University
Original Assignee
Jinjiang Hengyuan Technology Development Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinjiang Hengyuan Technology Development Co ltd filed Critical Jinjiang Hengyuan Technology Development Co ltd
Publication of CN105829312A publication Critical patent/CN105829312A/zh
Application granted granted Critical
Publication of CN105829312B publication Critical patent/CN105829312B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明涉及一种N‑苄基色胺酮衍生物及其制备方法和用途。本发明一种N‑苄基色胺酮类衍生物，其特征在于，所述衍生物具有式1所示的结构通式；其中，各基团的定义如说明书中所述。本发明化合物的制备方法操作简单、条件温和、收率高，易于工业化生产等优点。本发明所述的N‑苄基色胺酮衍生物具有优良的吲哚胺‑2,3‑双加氧酶(IDO)抑制活性，可应用于治疗具有IDO介导的色氨酸代谢的病理学特征的疾病。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201480067750.9A 2013-11-12 2014-11-12 一种n-苄基色胺酮衍生物及其制备方法和应用 Active CN105829312B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013105605720 2013-11-12
CN201310560572.0A CN103570727B (zh) 2013-11-12 2013-11-12 一种n-苄基色胺酮衍生物及其制备方法和应用
PCT/CN2014/090947 WO2015070766A1 (zh) 2013-11-12 2014-11-12 一种n-苄基色胺酮衍生物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN105829312A true CN105829312A (zh) 2016-08-03
CN105829312B CN105829312B (zh) 2018-09-28

Family

ID=50043506

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310560572.0A Active CN103570727B (zh) 2013-11-12 2013-11-12 一种n-苄基色胺酮衍生物及其制备方法和应用
CN201480067750.9A Active CN105829312B (zh) 2013-11-12 2014-11-12 一种n-苄基色胺酮衍生物及其制备方法和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310560572.0A Active CN103570727B (zh) 2013-11-12 2013-11-12 一种n-苄基色胺酮衍生物及其制备方法和应用

Country Status (11)

Country Link
US (1) US10059712B2 (zh)
EP (1) EP3070089B1 (zh)
JP (1) JP6629218B2 (zh)
KR (1) KR20160103986A (zh)
CN (2) CN103570727B (zh)
AU (1) AU2014350729B2 (zh)
CA (1) CA2930203A1 (zh)
EA (1) EA201690915A1 (zh)
MX (1) MX2016006217A (zh)
WO (1) WO2015070766A1 (zh)
ZA (1) ZA201603889B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108969522A (zh) * 2017-06-05 2018-12-11 复旦大学 N-苄基色胺酮类衍生物作为色氨酸双加氧酶(tdo)抑制剂的用途

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CN103570726B (zh) * 2013-07-15 2016-04-06 上海天慈生物谷生物工程有限公司 N-烷基色胺酮衍生物及其制备方法和应用
CN103570727B (zh) 2013-11-12 2015-08-19 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用
CN104844607B (zh) * 2015-03-26 2018-02-16 玉林师范学院 一种具有抗肿瘤活性的色胺酮溴代衍生物及其合成方法
CN105218476B (zh) * 2015-10-29 2018-03-13 上海天慈生物谷生物工程有限公司 一种治疗肺癌药物的制备方法
CN105330666B (zh) * 2015-11-27 2018-10-30 西北大学 色胺酮衍生物、合成方法及其药用用途
CN106928230B (zh) * 2015-12-30 2021-03-19 苏州如鹰生物医药有限公司 N-芳基、苄基色胺酮及其衍生物在制备hIDO2抑制剂中的用途
CN106928229B (zh) * 2015-12-30 2021-03-19 苏州如鹰生物医药有限公司 色胺酮及其衍生物在制备hIDO2抑制剂中的用途
CN107141292B (zh) * 2016-03-01 2019-02-12 华中师范大学 一种色胺酮类化合物的制备方法
US10669273B2 (en) * 2016-04-05 2020-06-02 Peking University Use of aza-tryptanthrin derivatives as inhibitors of IDO1 and/or TDO
CN110191709A (zh) 2017-01-17 2019-08-30 德州大学系统董事会 可用作吲哚胺2,3-双加氧酶和/或色氨酸双加氧酶抑制剂的化合物
CN107286165B (zh) * 2017-06-09 2019-07-26 扬州大学 合成色胺酮类化合物的方法
EP3823604A4 (en) 2018-07-17 2022-03-16 Board of Regents, The University of Texas System COMPOUNDS USEFUL AS INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE INHIBITORS
CN110734423B (zh) * 2018-07-18 2022-07-08 复旦大学 一类吲哚醌类吲哚胺-2,3-双加氧酶抑制剂及其药用用途
CN111135178A (zh) * 2018-11-02 2020-05-12 苏州如鹰生物医药有限公司 色胺酮衍生物治疗神经系统疾病的用途
CN110041335B (zh) * 2019-04-24 2022-01-07 同济大学 一种提高色胺酮的水溶性的方法、色胺酮衍生物及其制备方法和应用
CN110294740A (zh) * 2019-06-20 2019-10-01 同济大学 一种n-苄基氨基酸水溶性色胺酮及其制备方法和应用
CN110183454B (zh) * 2019-06-20 2022-01-07 同济大学 一种含1,2,3-三氮唑的色胺酮及其制备方法和应用
CN110283192B (zh) * 2019-07-18 2021-08-06 同济大学 一种含硼酸的色胺酮衍生物的制备方法及应用
CN110903449B (zh) * 2019-12-02 2022-09-06 大连理工大学 一种靛红芳烃共聚物、制备方法及应用
CN112724147B (zh) * 2020-12-23 2022-03-15 合肥工业大学 4(3h)-喹唑啉酮类化合物的制备方法
CN112641728A (zh) * 2020-12-27 2021-04-13 陕西中医药大学 一种色胺酮纳米脂质体及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068458A (en) * 1989-06-30 1991-11-26 Beecham Group P.L.C. Chemical process for halogenating 2-methyl-6-methoxynaphthalene
US5420259A (en) * 1991-05-08 1995-05-30 Basf Aktiengesellschaft Tryptanthrine derivatives
CN101843618A (zh) * 2010-02-26 2010-09-29 复旦大学 小檗碱及其衍生物在制备吲哚胺2,3-双加氧酶抑制剂中的用途
CN102532144A (zh) * 2012-01-20 2012-07-04 辽宁思百得医药科技有限公司 一种新型吲哚胺-2，3-双加氧酶抑制剂及其制备方法和用途
CN102579452A (zh) * 2012-01-20 2012-07-18 辽宁思百得医药科技有限公司 色胺酮类化合物的制备方法及其在制备ido抑制剂中的新用途
CN103570727A (zh) * 2013-11-12 2014-02-12 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441955A (en) * 1993-11-19 1995-08-15 Pathogenesis Corporation Indolo[2,1-biquinazoline-6,12-dione antibacterial compounds and methods of use thereof
JP3272189B2 (ja) * 1994-10-18 2002-04-08 京セラミタ株式会社 ナフチレンジアミン誘導体とそれを用いた電子写真感光体
AU765401B2 (en) 1998-09-30 2003-09-18 Wrair Walter Reed Army Institute Of Research Indolo(2,1-b)quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith
DE50008328D1 (de) * 1999-04-14 2004-11-25 Max Zeller & Soehne Ag Romansh ARZNEIMITTEL ZUR HEMMUNG DES NF-kB TRANSKRIPTIONSFAKTORS
CA2513655C (en) 2003-01-21 2011-11-22 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
RS54876B1 (sr) 2005-05-10 2016-10-31 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
GB0516570D0 (en) * 2005-08-12 2005-09-21 Astrazeneca Ab Amide derivatives
US20130281397A1 (en) * 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
CN103054870A (zh) * 2013-01-08 2013-04-24 复旦大学 色胺酮类化合物作为吲哚胺2,3-双加氧酶抑制剂的用途
SG11201507255QA (en) 2013-03-14 2015-10-29 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
JP6478991B2 (ja) 2013-07-11 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｄｏ阻害剤
CN103570726B (zh) 2013-07-15 2016-04-06 上海天慈生物谷生物工程有限公司 N-烷基色胺酮衍生物及其制备方法和应用
WO2015082499A2 (en) 2013-12-03 2015-06-11 Iomet Pharma Ltd Pharmaceutical compound
GB201322673D0 (en) 2013-12-20 2014-02-05 Tpp Global Dev Ltd Screening method
JP2017505346A (ja) 2014-02-12 2017-02-16 アイティーオス セラペウティクス 新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068458A (en) * 1989-06-30 1991-11-26 Beecham Group P.L.C. Chemical process for halogenating 2-methyl-6-methoxynaphthalene
US5420259A (en) * 1991-05-08 1995-05-30 Basf Aktiengesellschaft Tryptanthrine derivatives
CN101843618A (zh) * 2010-02-26 2010-09-29 复旦大学 小檗碱及其衍生物在制备吲哚胺2,3-双加氧酶抑制剂中的用途
CN102532144A (zh) * 2012-01-20 2012-07-04 辽宁思百得医药科技有限公司 一种新型吲哚胺-2，3-双加氧酶抑制剂及其制备方法和用途
CN102579452A (zh) * 2012-01-20 2012-07-18 辽宁思百得医药科技有限公司 色胺酮类化合物的制备方法及其在制备ido抑制剂中的新用途
CN103570727A (zh) * 2013-11-12 2014-02-12 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用
CN103570727B (zh) * 2013-11-12 2015-08-19 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108969522A (zh) * 2017-06-05 2018-12-11 复旦大学 N-苄基色胺酮类衍生物作为色氨酸双加氧酶(tdo)抑制剂的用途
CN108969522B (zh) * 2017-06-05 2023-03-28 复旦大学 N-苄基色胺酮类衍生物作为色氨酸双加氧酶(tdo)抑制剂的用途

Also Published As

Publication number Publication date
MX2016006217A (es) 2017-02-23
US10059712B2 (en) 2018-08-28
CA2930203A1 (en) 2015-05-21
KR20160103986A (ko) 2016-09-02
AU2014350729A1 (en) 2016-06-16
CN105829312B (zh) 2018-09-28
AU2014350729B2 (en) 2019-01-03
CN103570727B (zh) 2015-08-19
EP3070089A4 (en) 2017-04-26
WO2015070766A1 (zh) 2015-05-21
EP3070089A1 (en) 2016-09-21
EA201690915A1 (ru) 2017-02-28
US20160297822A1 (en) 2016-10-13
CN103570727A (zh) 2014-02-12
JP2016535788A (ja) 2016-11-17
ZA201603889B (en) 2019-09-25
EP3070089B1 (en) 2019-10-16
JP6629218B2 (ja) 2020-01-15

Similar Documents

Publication Publication Date Title
CN105829312A (zh) 一种n-苄基色胺酮衍生物及其制备方法和应用
JP2016535788A5 (zh)
CN103694238B (zh) No供体型苦参碱衍生物、其制备方法及医药用途
EP3495354A1 (en) Ido1 inhibitor and preparation method and application thereof
CN103864793B (zh) 取代嘌呤-9-乙酰氨基异羟肟酸类组蛋白去乙酰化酶抑制剂及制备方法和应用
US20190169163A1 (en) Quinoline derivative and use thereof
CN102311395A (zh) 喹唑啉环取代的二苯脲类衍生物及其用途
CN105254628B (zh) 吡唑并吡啶类抗肿瘤化合物及其制备方法和应用
CN112480140B (zh) C5-位取代汉防己甲素衍生物及其制备方法和应用
CN101973989A (zh) 一种噻唑酰胺类化合物及其在治疗恶性肿瘤中的药物用途
CN110885332B (zh) 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用
CN109400632B (zh) 一种含n-甲基依诺沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
CN106146584B (zh) 新型胞苷衍生物二聚体及其应用
CN110041335B (zh) 一种提高色胺酮的水溶性的方法、色胺酮衍生物及其制备方法和应用
CN109369676B (zh) 一种双-氟喹诺酮噁二唑脲类n-乙酰诺氟沙星衍生物及其制备方法和应用
CN110283192A (zh) 一种含硼酸的色胺酮衍生物的制备方法及应用
CN110237076A (zh) PDINCl在制备抗肿瘤药物中的应用
CN103450113B (zh) 一种取代噻二嗪三酮类衍生物及其制备方法与应用
JP2020531592A (ja) 重水素化インドールアミン２，３−ジオキシゲナーゼ阻害剤及びその使用
CN109369674B (zh) 一种含左氧氟沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
CN109761998B (zh) 双-氟喹诺酮噻二唑脲类氟罗沙星衍生物的制备和应用
CN103880700B (zh) O-肉桂酰-氟苯水杨酰胺类化合物及其在制备抗宫颈癌药物中的应用
CN109438472B (zh) 一种含n-甲基加替沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
CN109438482B (zh) 一种含芦氟沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
CN109438481B (zh) 一种含n-甲基莫西沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1226722

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant